The EPS miss relative to consensus may create near-term pressure, but the revenue beat and raised guidance are positive. The merger close on November 2 is the key catalyst; post-merger financials and synergy realization will determine the stock's trajectory.
Price Chart
Executive Summary
Supernus Pharmaceuticals reported Q3 2026 total revenue of $226.8M, an 18% YoY increase, beating the $217.6M consensus. GAAP diluted EPS was $0.35, below the $0.49 consensus estimate. The company raised its full-year 2026 revenue guidance to $875M-$900M from $860M-$890M, and the merger with Indivior is expected to close on November 2, 2026.
Key Financial Metrics
Key Facts
- Total revenue of $226.8M in Q3 2026, up 18% YoY, above consensus of $217.6M.
- GAAP diluted EPS of $0.35, below consensus of $0.49.
- Combined revenue of four growth products (Qelbree, GOCOVRI, ZURZUVAE, ONAPGO) was $192.2M, up 29% YoY.
- Qelbree net sales $90.8M, up 12% YoY; GOCOVRI net sales $42.6M, up 4% YoY; ONAPGO net sales $17.1M, up 151% YoY; ZURZUVAE collaboration revenue $41.7M, up 107% YoY.
- Full-year 2026 revenue guidance raised to $875M-$900M from $860M-$890M.
- Merger with Indivior expected to close November 2, 2026; combined company to trade as SUPN.
- Cash, cash equivalents, and marketable securities were $359.5M as of September 30, 2026.
Financial Impact
Revenue beat consensus by $9.2M (4.2%); EPS missed by $0.14 (28.6%). Full-year guidance raised by $15M at midpoint.
Risk Factors
- EPS missed consensus by $0.14, which could weigh on the stock despite revenue beat.
- Merger with Indivior may face integration risks and may not achieve the projected $125M in annual cost synergies.
- Declining sales of legacy products Trokendi XR (down 2% in Q3) and Oxtellar XR (down 34% in Q3) continue to erode.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3391818 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 3d ago | 8-K | No price | awaiting T+5 | awaiting T+5 | No price |
Oct 29, 2026 3d ago | Press Release | $41.84 | awaiting T+5 | awaiting T+5 | $41.92 (+0.19%) |
Oct 26, 2026 6d ago | 8-K | $40.96 | awaiting T+5 | awaiting T+5 | $41.92 (+2.34%) |
Oct 26, 2026 6d ago | Court Ruling | $40.96 | awaiting T+5 | awaiting T+5 | $41.92 (−2.34%) |
Oct 21, 2026 10d ago | 8-K | $42.07 $41.84 | ▼ −0.55% | ▼ −1.25% | $41.92 (−0.36%) |
Oct 19, 2026 13d ago | 8-K | $41.23 $40.54 | ▼ −1.67% | ▼ −1.70% | $41.92 (+1.67%) |
Oct 19, 2026 13d ago | Press Release | $39.84 $40.63 | ▲ +1.98% | ▲ +2.13% | $41.92 (+5.22%) |
Oct 6, 2026 26d ago | 425 | $42.83 $42.01 | ▼ −1.91% | ▼ −1.78% | $41.92 (−2.12%) |
Oct 6, 2026 26d ago | DEFA14A | $42.83 $42.01 | ▼ −1.91% | ▼ −1.78% | $41.92 (−2.12%) |
Sep 11, 2026 7w ago | DEFM14A | $41.49 $42.78 | ▲ +3.11% | ▲ +3.00% | $41.92 (+1.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers